Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Welcome, Guest. Please login or register.
April 24, 2014, 03:24:38 AM

Login with username, password and session length

  • Total Posts: 621213
  • Total Topics: 46799
  • Online Today: 229
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 1
Guests: 151
Total: 152


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Bionor Pharma's "Kick, Kill & Boost" Strategy-- Romidepsin Chosen as Kick  (Read 835 times)

0 Members and 1 Guest are viewing this topic.

Offline Tadeys

  • Member
  • Posts: 159
Oslo 10.09.2013 - Bionor Pharma ASA (OSE: BIONOR) announces that the Company has chosen romidepsin for the planned combination study with Vacc-4x, after considering various HDAC inhibitors (HDACi). Romidepsin is marketed in the US as Istodax® by Celgene Corporation Inc.

The "Kick, Kill" study is planned to be conducted by the HIV research team at
Aarhus University Hospital, led by Prof. Lars Østergaard. Prof.  Østergaard
presented the background and expectations of the study at Bionor Pharma's
Capital Markets Day in June.

"HDAC inhibitors have recently shown the ability to release HIV from the
lymphatic system where the virus hides, and positive data from this new HDAC
inhibitor research will be published shortly" says Prof. Østergaard. He
continues; "The combination of providing Bionor Pharma's T-cell killing vaccine
Vacc-4x, followed by an HDAC inhibitor may represent a new treatment that can
completely or periodically enable patients to forego continuous treatment with
HIV medications, and thereby lead to a Functional Cure. Romidepsin is chosen
because it has proven to be the most effective HDAC inhibitor to release HIV
from virus reservoirs where virus is hiding. We are very positive about this
study which represents a new way to treat HIV, and have expectations that this
can improve the current treatment of HIV".

"Bionor Pharma is excited about the cooperation with the HIV scientists at
Aarhus University Hospital, who are in the forefront within this novel field of
HIV research" says Dr. Anker Lundemose, CEO Bionor Pharma. "Vacc-4x has
previously demonstrated  its ability to induce killing of virus producing cells
by training the immune system, which seems to be essential as soon as an HDAC inhibitor has activated such cells from being dormant in the reservoir".

Bionor Pharma will be the sponsor for the combination study at Aarhus University Hospital, and the plan is to submit the application with study protocol to the Danish Health Authorities by Q4 2013. Bionor Pharma filed patents on the combination of its vaccines with other treatment modalities including IMiD and HDACi earlier this year. The original romidepsin patent has expired.

The execution of the new "Kick Kill & Boost" strategy depends on funding of the
Vacc-4x & HDACi combination trial. To this end, the Company continues to
evaluate various strategic and financial opportunities, and will continue to
update the market on these efforts during H2 2013.


Offline Matts

  • Member
  • Posts: 184
Re: Bionor Pharma's "Kick, Kill & Boost" Strategy-- Romidepsin Chosen as Kick
« Reply #1 on: November 19, 2013, 04:57:38 PM »
I am quite disappointed in the Scandinavians. What a PR-disaster with the Panobinostat trial in the Summer ("HIV cure on the brink" bla bla ). At least they could publish the results before they start a new project. Did it work or not?

Anyway, I wish Ole Soogard and Bionor the best for the future. If Istadax doesn't work then it's over for Bionor and Aarhus regarding to HIV. It is 1000-20000 fold stronger than SAHA. Maybe it will be the breakthrough :)



Terms of Membership for these forums

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.